Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration

LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft … [Read more…]

Onera Launches Innovative Sleep Diagnostics Solution in Europe

Onera Health announces the launch of Onera Polysomnography-as-a-Service in selected European markets at the International Congress 2022 of the European Respiratory Society (ERS). EINDHOVEN, The Netherlands–(BUSINESS WIRE)–Onera Health, a leader in transforming sleep medicine and remote monitoring, announced today the official launch of its ground-breaking solution to diagnose sleep disorders in Europe. The service is … [Read more…]

Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022

Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK cells by Innate’s Chief Scientific Officer, Eric Vivier, DVM, PhD, AstraZeneca-sponsored Phase 2 NeoCOAST study of neoadjuvant durvalumab alone or combined with novel agents, including monalizumab, in patients with … [Read more…]

Slingshot Biosciences, Inc. Partners With BIOKÉ to Distribute Synthetic Cells Throughout the Netherlands, Belgium, and Luxembourg (Benelux)

EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC., the makers of synthetic control cells for cell analysis applications, including flow cytometry, enabling precise, reliable, and repeatable results, today announced they had extended their distribution channel through a new agreement with BIOKÉ, an experienced and knowledgeable company from the Netherlands that provides innovative products with the highest quality in … [Read more…]

CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress

Oral presentation in “Investigational Immunotherapy” session on Saturday, September 10 at 2:45 PM CEST MUNICH–(BUSINESS WIRE)–CatalYm today announced that the mature results from its Phase 1, first-in-human trial “GDFATHER-1” (GDF-15 antibody-mediated human effector cell relocation) will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022. The trial evaluated … [Read more…]

Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present preclinical data on WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product, at the European Society for Medical Oncology … [Read more…]

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

Zanidatamab zovodotin shown to have manageable safety profile with encouraging, single-agent anti-tumor activity in patients with HER2+ cancers Results to be reviewed in an oral presentation at European Society for Medical Oncology (ESMO) Congress 2022 in Paris Monday, September 12 at 5:25 pm Central European Summer Time (CEST) VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. … [Read more…]

New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status

— Progression-Free Survival Efficacy of Trodelvy Consistent with That Observed in the TROPiCS-02 Intention-to-Treat Population — — Results Presented at ESMO 2022 Highlight Trodelvy as a Potential Treatment Option in HR+/HER2-Low and IHC0 Status Metastatic Breast Cancer — FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post hoc subgroup … [Read more…]

Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022

In Phase 1 studies, cudetaxestat displayed low potential for drug-drug interactions when dosed with approved therapies for idiopathic pulmonary fibrosis (IPF) and other commonly used medications Cudetaxestat was well tolerated and showed no reports of treatment-related serious adverse events, including when co-administered with either pirfenidone or nintedanib, in healthy volunteers Cudetaxestat, an investigational non-competitive autotaxin … [Read more…]

Fresenius Kabi and AABB Celebrate 17th Annual Blood Collectors Week from September 4-10, 2022

Honoring blood collection professionals and their lifesaving impact on patient care LAKE ZURICH, Ill. & BETHESDA, Md.–(BUSINESS WIRE)–#BloodCollectorsWeek–Fresenius Kabi and AABB announced today the official start of the 17th annual Blood Collectors Week celebration, which runs September 4-10, 2022. Throughout the week, blood collectors are being honored for the lifesaving work they do each day … [Read more…]